Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an Immune-Boosting drug stop lung cancer from returning?

NCT ID NCT02273375

Prevention Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

This phase III trial tests whether the immunotherapy drug durvalumab (MEDI4736) can prevent non-small cell lung cancer from returning after patients have surgery and possibly chemotherapy. Participants have completely resected stage IB, II, or IIIA lung cancer and are randomly assigned to receive either durvalumab or a placebo. Researchers compare how long patients remain disease-free to see if the drug offers a benefit over no further treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
durvalumab (MEDI4736), an immunotherapy drug
What this could lead to
If it works, giving immunotherapy after surgery could become a standard way to keep early-stage lung cancer from coming back.
What could go wrong
The drug may not stop cancer from returning, and it can cause immune-related side effects. This is a large phase III trial, but results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,415 people

The number who actually took part.

Started

Feb 2015

Finished

Sep 2026

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung. according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7). Patients with large-cell neuroendocrine carcinomas are not eligible. * Patients must be classified post-operatively as Stage IB (≥ 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria). * Complete surgical resection of the primary NSCLC is also mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or VATS techniques Note: Patients with synchronous primary tumours will not be eligible due to the potential uncertainty regarding their appropriate PD-L1 status. Prior Systemic Therapy: * Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible. * Patients may have received prior post-operative platinum based chemotherapy as per standard of care. * No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible. Radiation: • Patients with N2 disease only who receive adjuvant post-operative radiation therapy are eligible provided they meet the protocol specified timing criteria for surgery, adjuvant chemotherapy and randomization. Pre-operative radiation therapy is not permissible. * The patient must have an ECOG performance status of 0, 1. * Hematology: . Absolute neutrophil count ≥ 1.5 x 109/L or ≥ 1,500/µl Platelets ≥ 100 x 109/L or ≥ 100,000/µl * Biochemistry: Total bilirubin\* ≤ institutional upper limit of normal Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal AST(SGOT) and ALT(SGPT) ≤ 2.5 x institutional upper limit of normal Creatinine Clearance ≥ 40 ml/min \* excluding Gilbert's syndrome Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula: Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in μmol/L Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in μmol/L * Patient able and willing to complete the QoL, economics and other questionnaires. The baseline assessment must already have been completed within required timelines prior to randomization. Inability (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible * Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate * Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up * Protocol treatment is to begin within 2 working days of patient randomization Exclusion Criteria: * Patients with a history of other malignancies, except: * adequately treated non-melanoma skin cancer, * curatively treated in-situ cancer, or * other malignancies curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy. * A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC). * History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's disease and/or psoriasis not requiring systemic therapy within the last two years from randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement are not excluded. * History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization\* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy. * Live attenuated vaccination administered within 30 days prior to randomization. * History of hypersensitivity to MEDI4736 or any excipient. * Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, must have a LVEF \> 50% within 12 weeks prior to randomization. * Concurrent treatment with other investigational drugs or anti-cancer therapy. * Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to: * known clinical diagnosis of tuberculosis; * known active hepatitis B infection (positive HBV surface antigen (HBsAg)). Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible; * known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA; * known human immunodeficiency virus infection (positive HIV antibodies). * known pneumonitis or pulmonary fibrosis with clinically significant impairment of pulmonary function * Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer

Contacts and locations

Locations

  • Study site

    Lévis, Quebec, G6V 3Z1, Canada

  • A.O. Busto Arsizio - P.O. Saronno

    Saronno, VA, 21047, Italy

  • AOU Integrata Verona Policlinico GB

    Verona, VR, 37134, Italy

  • AOU Ospedali Riuniti Umberto I

    Torrette, AN, 60126, Italy

  • AOU Policlinico Vittorio Emanuele UOC di Oncologia

    Catania, Catania, 95125, Italy

  • AP-HP Hopital Tenon

    Paris, Cedex 20, 75970, France

  • Academical Hospital Maastricht

    Maastricht, 622G HX, Netherlands

  • Ajou University Hospital

    Suwon, Gyeonggi-do, 443-380, South Korea

  • Algoma District Cancer Program

    Sault Ste. Marie, Ontario, P6B 0A8, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, S4T 7T1, Canada

  • Amphia ziekenhuis

    Breda, North Brabant, 4818 CK BREDA, Netherlands

  • Annemasse - Centre Hospitalier Alpes Leman

    Contamine-sur-Arve, 74130, France

  • Austin Hospital

    Heidelberg, Victoria, 3084, Australia

  • Azienda Ospedaliera S. Camillo-Forlanin

    Rome, 00152, Italy

  • Azienda Ospedaliera San Giuseppe Moscati

    Avellino, AV, 83100, Italy

  • Azienda Ospedaliera di Perugia Santa Maria

    Perugia, PG, 06129, Italy

  • Azienda Ospedaliera di Rilievo Nazionale

    Naples, 80131, Italy

  • Azienda USL di Piacenza, Ospedale Gugliemimo Salieto

    Piacenza, 29100, Italy

  • BCCA - Abbotsford Centre

    Abbotsford British Columbia, British Columbia, V2S 0C2, Canada

  • BCCA - Fraser Valley Cancer Centre

    Surrey, British Columbia, V3V 1Z2, Canada

  • BCCA - Vancouver Cancer Centre

    Vancouver, British Columbia, V5Z 4E6, Canada

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Bayonne - Centre Hospitalier

    Bayonne, 64100, France

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Border Medical Oncology

    Wodonga, Victoria, 3690, Australia

  • Boulogne - Ambroise Pare

    Boulogne, 92104, France

  • CH de la Region d'Annecy

    Metz-Tessy, 74370, France

  • CHITS Toulon Sainte Musse

    Toulon, 83056, France

  • CHRU de Tours - Hopital Bretonneau

    Tours, Tours Cedex 9, 37044, France

  • CHU - Angers

    Angers, 49033, France

  • CHU Hopital du Bocage

    Dijon, 21079, France

  • CHU de Rouen

    Rouen, 76031, France

  • CHUM-Centre Hospitalier de l'Universite de Montreal

    Montreal, Quebec, H2X 3E4, Canada

  • CRLCC - Paoli-Calmette

    Marseille, BP, 156, France

  • Caen - CHU

    Caen, 14000, France

  • Campbelltown Hospital

    Campbelltown, New South Wales, 2560, Australia

  • Canberra Hospital

    Garran, ACT 2605, Australia

  • CancerCare Manitoba

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Centre Antoine Lacassagne - Nice

    Nice, 06189, France

  • Centre Hospitalier - Avignon

    Avignon, 84000, France

  • Centre Hospitalier General de Pau

    Pau, 64000, France

  • Centre Hospitalier Intercommunal - Elbeuf

    Elbeuf, 76503, France

  • Centre Hospitalier Intercommunal de Creteil

    Créteil, 94000, France

  • Centre Hospitalier Lyon Sud

    Lyon, 69495, France

  • Centre Hospitalier Regional Hopital de la Source

    Orléans, 45000, France

  • Centre Hospitalier Rene Dubos

    Pontoise, 95301, France

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, 91100, France

  • Centre Hospitalier de Chambery

    Chambéry, 73000, France

  • Centre Hospitalier de Cholet

    Cholet, 49325, France

  • Centre Hospitalier de Mulhouse

    Mulhouse, 68070, France

  • Centre Hospitalier de Perigueux

    Périgueux, 24019, France

  • Centre Hospitalier de Saint-Quentin

    Saint-Quentin, 02100, France

  • Centre Hospitalier departemental

    La Roche-sur-Yon, 85925, France

  • Centre Hospitalier du Mans

    Le Mans, 72037, France

  • Centre Hospitalier les Chanaux

    Mâcon, 71018, France

  • Centre Integre Universitaire De Sante Et De Services

    Montreal, Quebec, H4J 1C5, Canada

  • Centre hospitalier universitaire de Montpellier

    Montpellier, Cedex 05, 34295, France

  • Centro de Oncologia e Radioterapia (COR) Mae de Deus

    Porto Alegre, Rio Grande do Sul, 90110270, Brazil

  • Centro di Riferimento Oncologico - CRO

    Aviano, PN, 33081, Italy

  • Centrul de Oncologie Sf Nectarie

    Craiova, 200347, Romania

  • Cetus Hospital Dia Oncologia

    Belo Horizonte, Minas Gerais, 30110-022, Brazil

  • Chang-Gung Memorial Hospital - Chiayi

    Chiayi City, Taiwan, 613, Taiwan

  • Chang-Gung Memorial Hospital - Kaohsiung

    Kaohsiung, Taiwan, 833, Taiwan

  • Chang-Gung Memorial Hospital - Linkou

    Taoyuan, Taiwan, 333, Taiwan

  • Chiba University Hospital

    Chiba, Chiba, 260-8677, Japan

  • China Medical University Hospital

    Taichung, 404, Taiwan

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, 2050, Australia

  • Christchurch Hospital

    Christchurch, New Zealand

  • Chung Ang University Hospital

    Seoul, Dongjak gu, 156-755, South Korea

  • Chungbuk National University Hospital

    Cheongju-si, North Chungcheong, 362-711, South Korea

  • Clermont-Ferrand - CHU

    Clermont-Ferrand, 63003, France

  • Clinica de Neoplasias Litoral

    Itajaí, Santa Catarina, 88301220, Brazil

  • Coffs Habour Health Campus - NCCI

    Coffs Harbour, New South Wales, 2450, Australia

  • Complejo Asistencial Universitario de Leon

    León, Leon, 24071, Spain

  • Conformal Med Terra HIFU

    Bucharest, 031864, Romania

  • Cross Cancer Institute

    Edmonton, Alberta, T6G 1Z2, Canada

  • Dnipropetrovsk City Clinical Hospital No.4

    Dnipropetrovsk, 49102, Ukraine

  • Dott. Fortunato Ciardiello,Cattedra Oncologia Medica

    Naples, 80131, Italy

  • Dr. H. Bliss Murphy Cancer Centre

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • E-Da Hospital

    Kaohsiung City, Taiwan, 82445, Taiwan

  • Epworth HealthCare - Richmond

    Richmond, Victoria, 3121, Australia

  • Erasmus Medical Center (EMC)

    Rotterdam, Netherlands, Netherlands

  • European Institute of Oncology

    Milan, 20141, Italy

  • Faculdade de Medicina do ABC

    São Paulo, Santo Andre, 09060870, Brazil

  • Far Eastern Memorial Hospital

    New Taipei City;, Taiwan, 220, Taiwan

  • Fiona Stanley Hospital

    Murdoch, Western Australia, 6150, Australia

  • Flinders Medical Center

    Adelaide, 5042, Australia

  • Fondation Hopital Saint Joseph

    Paris, 75014, France

  • Fondazione Salvatore Maugeri Oncologia Medica

    Pavia, PV, 27100, Italy

  • Frankston Hospital - Peninsula Oncology Centre

    Frankston, Victoria, 3199, Australia

  • Free University Hospital

    Amsterdam, Netherlands, Netherlands

  • Fujian Province Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Fundacao Faculdade Regional de Medicina

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Fundacion Jimenez Diaz

    Madrid, Madrid, 28040, Spain

  • Gifu Univiesity Hospital

    Gifu, Gifu, 501-1194, Japan

  • Gosford Hospital

    Gosford, New South Wales, 2250, Australia

  • Guangdong General Hospital

    Guangzhou, Guangdong, 510080, China

  • Gunma University Hospital

    Maebashi, Gunma, 371-8511, Japan

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • HIA Percy

    Clamart, 92141, France

  • Health Sciences North

    Greater Sudbury, Ontario, P3E 5J1, Canada

  • Hematology and Oncology Associates of NEPA

    Dunmore, Pennsylvania, 18512, United States

  • Henan province Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Hiroshima City Hiroshima Citizens Hospital

    Hiroshima, Hiroshima, 730-8518, Japan

  • Hiroshima University Hospital

    Hiroshima, 734-8551, Japan

  • Hoapital Quiron Dexeus

    Barcelona, Barcelona, 08028, Spain

  • Hopital Albert Michallon

    Grenoble, Cedex 9, 38043, France

  • Hopital Avicenne

    Bobigny, CEDEX 93009, France

  • Hopital Bichat

    Paris, 75877, France

  • Hopital Europeen

    Marseille, 13291, France

  • Hopital Jean Minjoz

    Besançon, 25030, France

  • Hopital Larrey

    Toulouse, 31059, France

  • Hopital Louis Pasteur

    Colmar, 68024, France

  • Hopital Saint Louis

    Paris, 75010, France

  • Hopital de la Croix-Rousse

    Lyon, Cedex 04, 69317, France

  • Hospital Clinico San Carlos

    Madrid, Madrid, 28040, Spain

  • Hospital Duran i Reynals

    Barcelona, Barcelona, 08907, Spain

  • Hospital Evangelico de Cachoeiro de Itapemirim

    Cachoeiro de Itapemirim, Espírito Santo, 29308020, Brazil

  • Hospital General Universitario de Valencia

    Valencia, Valencia, 46014, Spain

  • Hospital General de Alicante

    Alicante, Alicante, 03010, Spain

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona, 08916, Spain

  • Hospital Insular de Gran Canaria

    Las Palmas, Gran Canaria, 35016, Spain

  • Hospital Mutua de Terrassa

    Terrassa, Barcelona, 08221, Spain

  • Hospital Puerta de Hierro

    Madrid, Madrid, 28035, Spain

  • Hospital Son Llatzer

    Palma de Mallorca, Palma de Mallorca, 07198, Spain

  • Hospital Teresa Herrera

    A Coruña, Coruna, 15006, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Salamanca, 37007, Spain

  • Hospital Universitario la Princesa

    Madrid, Madrid, 28006, Spain

  • Hospital Vall d Hebron

    Barcelona, Barcelona, 08035, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Barcelona, 08041, Spain

  • Hospital of the University of Occupational and

    Kitakyushu, Fukuoka, 807-8556, Japan

  • Humber River Hospital

    Toronto, Ontario, M3M 0B2, Canada

  • Hyogo College of Medicine

    Nishinomiya-shi, Hyōgo, 663-8501, Japan

  • IRCCS Ospedale Oncologico Giovanni Paolo II

    Bari, BA, 70124, Italy

  • Institut Sainte Catherine

    Avignon, 84000, France

  • Institut de Cancerologie de la Loire

    Saint-Priest-en-Jarez, 42271, France

  • Instituto Clinico Humanitas

    Rozzano (MI), Lombardy, 20089, Italy

  • Instituto Nacional de Cancer (INCA)

    Rio de Janeiro, Rio de Janeiro, 20231050, Brazil

  • Instituto Tacchini de Pesquisa em Saude

    Bento Gonçalves, Rio Grande do Sul, 95700068, Brazil

  • Intstituto Scientifico Romangnolo

    Meldola, 47014, Italy

  • Isala

    Zwolle, Overijssel, 8025 AB, Netherlands

  • Istituti Fisioterapici Ospitalieri IFO Istituto

    Rome, RM, 00144, Italy

  • Japanese Red Cross Nagoya Daiichi Hospital

    Nagoya, Aichi-ken, 453-8511, Japan

  • Juntendo University Hospital

    Tokyo, Tokyo, 113-8431, Japan

  • Juravinski Cancer Centre at Hamilton Health Sciences

    Hamilton, Ontario, L8V 5C2, Canada

  • Kanagawa Cancer Center

    Yokohama, 241-0815, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, 920-8641, Japan

  • Kangbuk Samsung Hospital

    Seoul, Seoul, 03181, South Korea

  • Kansai Medical University Hospital

    Hirakata, Osaka, 573-1191, Japan

  • Kaohsiung Medical University

    Kaohsiung, Taiwan, 807, Taiwan

  • Keimyung University Dongsan Medical Center

    Daegu, Dalseogu, 42601, South Korea

  • Kingston Health Sciences Centre

    Kingston, Ontario, K7L 2V7, Canada

  • Kinki University Hospital Faculty of Medicine

    Ōsaka-sayama, Osaka, 589-8511, Japan

  • Klinika Onkologii i Radioterapii Uniwersyteckie

    Gdansk, 80-214, Poland

  • Koube University Hospital

    Kobe, Hyōgo, 650-0017, Japan

  • Kurashiki Central Hospital

    Kurashiki, Okayama-ken, 710-8602, Japan

  • Kyushu University Hospital

    Fukuoka, Fukuoka, 812-8582, Japan

  • Lakeridge Health Oshawa

    Oshawa, Ontario, L1G 2B9, Canada

  • Liga Norte Riograndense Contra o Cancer

    Natal, Rio Grande do Norte, 59075740, Brazil

  • Lille - Hopital Calmette

    Lille, 59037, France

  • Liverpool Cancer Therapy Centre, Liverpool Hospital

    Liverpool, New South Wales, 2170, Australia

  • London Regional Cancer Program

    London, Ontario, N6A 5W9, Canada

  • MHAT Nadezhda Hospital

    Sofia, 1330, Bulgaria

  • MHAT Serdika - Medical Oncology Clinic

    Sofia, 1003, Bulgaria

  • Mackay Memorial Hospital

    Taipei, Taiwan, 104, Taiwan

  • Marseille - Hopital Nord

    Marseille, 13915, France

  • Mater Medical Centre

    Brisbane, South, QLD, 4101, Australia

  • Medical Centre Synexus

    Sofia, 1784, Bulgaria

  • Monash Medical Centre

    Clayton, Victoria, 3168, Australia

  • Nagoya University Hospital

    Nagoya, Aichi-ken, 466-8560, Japan

  • Nanjing General Hospital

    Nanjing, Jiangsu, 210002, China

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • National Hospital Organization Kinki-Chuo

    Sakai, Osaka, 591-8555, Japan

  • National Hospital Organization Kure Medical Center

    Kure, Hiroshima, 737-0023, Japan

  • National Hospital Organization Kyushu Medical Center

    Fukuoka, Fukuoka, 810-8563, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, 791-0280, Japan

  • National Hospital Organization Yamaguchi

    Ube, Yamaguchi, 755-0241, Japan

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • National University Hospital

    Singapore, 119074, Singapore

  • Nepean Hospital

    Kingswood, New South Wales, 2751, Australia

  • Netherlands Cancer Institute

    Amsterdam, 1066 CX, Netherlands

  • Niagara Health System

    St. Catharines, Ontario, L2S 0A9, Canada

  • Northern Cancer Institute St Leonards

    St Leonards, New South Wales, 2065, Australia

  • Northern Jiangsu People Hospital

    Yangzhou, Jiangsu, 225000, China

  • Nouvel Hopital Civil Hopitaux

    Strasbourg, 67091, France

  • OCH - Ovidius Clinical Hospital

    Constanța, 905900, Romania

  • OUC Oncologia Medica - Presidio Ospedaliero

    Ravenna, RA, 48121, Italy

  • Odette Cancer Centre

    Toronto, Ontario, M4N 3M5, Canada

  • Oncologia Medica IRCCS Arcispedale Maria

    Reggio Emilia, RE, 42123, Italy

  • Oncological Institute "Ion Chiricuta"

    Cluj-Napoca, 3400, Romania

  • Oncology Institute Bucharest

    Bucharest, Romania

  • Osaka City General Hospital

    Osaka, Osaka, 534-0021, Japan

  • Osaka International Cancer Institute

    Osaka, Osaka, 537-8511, Japan

  • Ospedale S. Paolo - U.O. di Oncologia Medica

    Milan, MI, 20142, Italy

  • Ottawa Hospital Research Institute

    Ottawa, Ontario, K1H 8L6, Canada

  • PEI Cancer Treatment Centre

    Charlottetown, Prince Edward Island, C1A 8T5, Canada

  • PO A Perrino ASL Brindisi - UOC Oncologia Medica

    Brindisi, 72100, Italy

  • Paris - HEGP

    Paris, 75015, France

  • Paris - Institut Curie

    Paris, 75248, France

  • Polyclinique Bordeaux Nord

    Bordeaux, 33077, France

  • Princess Alexandra Hospital

    Brisbane, Queensland, 4102, Australia

  • QEII Health Sciences Centre

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Regional Health Authority B, Zone 2

    Saint John, New Brunswick, E2L 4L2, Canada

  • Regional Oncology Center

    Sumy, 40004, Ukraine

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, 7000, Australia

  • Royal Melbourne Hospital Research Foundation

    Parkville, Victoria, 3050, Australia

  • SC Oncolab SRL

    Craiova, 200385, Romania

  • Samodzielny Publiczny Szpital Specjalistyczny

    Zakopane, 34 500, Poland

  • Saskatoon Cancer Centre

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • Semmelweis University Pulmonology Department

    Budapest, Budapest, 1125, Hungary

  • Sendai Kousei Hospital

    Sendai, Miyagi, 980-0873, Japan

  • Shandong Cancer Hospital

    Jinan, Shandong, 250000, China

  • Sinai Health System

    Toronto, Ontario, M5G 1X5, Canada

  • Sir Charles Gairdner Hospital

    Perth, Western Australia, 6009, Australia

  • Sir run run shaw hospital School of Medicine

    Hangzhou, Zhejiang, 310016, China

  • Specjalistyczny Szpital im

    Szczecin, 70 891, Poland

  • Spital Lotus SRL

    Ploieşti, 100011, Romania

  • Spitalul de Psihiatrie Dr. Constantin Gorgos

    Bucharest, 30447, Romania

  • St John of God Subiaco

    Subiaco, Western Australia, 6008, Australia

  • St. George Hospital, Cancer Care Centre

    Kogarah, New South Wales, 2217, Australia

  • St. Vincent's Hospital

    Victoria Park, Victoria Park, 3065, Australia

  • Stronach Regional Health Centre at Southlake

    Newmarket, Ontario, L3Y 2P9, Canada

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575, Australia

  • Suporte Nutricional e Quimioterapia LTDA PRONUTRIR

    Fortaleza, Ceará, 60810180, Brazil

  • Suresnes - Foch

    Suresnes, 92151, France

  • Taipei Medical University - Shuang Ho Hospital

    New Taipei City, Taiwan, 235, Taiwan

  • Tergooi locatie Hilversum

    Hilversum, North Holland, 1213XZ, Netherlands

  • The Affiliated Hospital Of Qingdao University

    Qingdao, Shandong, 266003, China

  • The Affiliated Hospital Of Xuzhou Medical College

    Xuzhou, Jiangsu, 221000, China

  • The Catholic University of Korea Bucheon

    Bucheon-si, Gyeonggi-do, 420-717, South Korea

  • The Catholic University of Korea,

    Seoul, 137-701, South Korea

  • The First People Hospital of Yueyang

    Yueyang, Hunan, 414000, China

  • The Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • The Moncton Hospital

    Moncton, New Brunswick, E1C 6Z8, Canada

  • The People Hospital of Guangxi Zhuang Autonomous Reg

    Nanning, Guangxi, 530021, China

  • The Prince Charles Hospital

    Chermside, Queensland, 4032, Australia

  • The Reading Hospital Medical Center

    West Reading, Pennsylvania, 19611, United States

  • The Research Institute of the McGill University

    Montreal, Quebec, H4A 3J1, Canada

  • The Second Affiliated Hosp of Shantou Medical Colleg

    Shantou, Guangdong, 515041, China

  • The Second Xiangya Hospital of Central South Univer

    Changsha, Hunan, 410011, China

  • Thomas Jefferson University

    Philadelphia, Pennsylvania, 19107, United States

  • Thonon-les-Bains - Hopital Georges Pianta

    Thonon-les-Bains, 74203, France

  • Thunder Bay Regional Health Sciences Centre/Thunder

    Thunder Bay, Ontario, P7B 6V4, Canada

  • Tokyo Medical University Hospital

    Tokyo, Tokyo, 160-0023, Japan

  • Tom Baker Cancer Centre

    Calgary, Alberta, T2N 4N2, Canada

  • Tottori University Hospital

    Yonago, Tottori, 683-8504, Japan

  • Tri-Service General Hospital

    Taipei, 114, Taiwan

  • U.O. di Oncologia Medica Azienda Ospedaliera G Rummo

    Benevento, 82100, Italy

  • U.O. di Oncologia Ospedale Villa Scassi

    Genova, 16149, Italy

  • U.O.C. di Oncologia U.L.S.S. 13

    Mirano, 30035, Italy

  • UMC Groningen

    Groningen, Provincie Groningen, 9713 GZ, Netherlands

  • UOC Oncologia Medica II Instituto Oncologio Veneto

    Padova, 35128, Italy

  • USC Norris/Comprehensive Cancer Centre

    Los Angeles, California, 9003308, United States

  • Uijeongbu ST Marys Hospital

    Gyeonggi-do, Gyeonggi-do, 11765, South Korea

  • Unita Sperimentazioni Cliniche Istituto per lo

    Naples, 80131, Italy

  • Universita Federico II UOC Oncologia Medica

    Naples, 80131, Italy

  • Universitair medisch centrum Nijmegen st Radboud

    Nijmegen, Gelderland, 6525 GA, Netherlands

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

  • University Institute of Cardiology and

    Québec, Quebec, G1V 4G5, Canada

  • University of Florida

    Gainesville, Florida, 32610-0277, United States

  • Versailles - CH Andre Mignot

    Le Chesnay, 78157, France

  • Veterans General Hospital - Taipei

    Taipei, Taiwan, 112, Taiwan

  • Veterans Health Service Medical Center

    Seoul, Gangdong-gu, 134-791, South Korea

  • Villefranche sur Saone - CH

    Villefranche-sur-Saône, 69655, France

  • Vinnytsia Regional Clinical Oncology Dispensary

    Vinnitsia, 21029, Ukraine

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, 221000, China

  • Yunnan Provincial Cancer Hospital

    Kunming, Yunnan, 650118, China

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.